insights INSIGHTS 03Oct October 3, 2024 How EMA’s Expedited Pathways and Scientific Advice Are Shaping Drug Approvals 02Aug August 2, 2024 Safety Testing of Allogeneic Cells used in Cell Based Medical Products 24May May 24, 2024 Redesigned Pre-Submission Meetings for ANDAs with the US FDA 18Mar March 18, 2024 Importance of Collaboration between Global Regulators 19Feb February 19, 2024 The Advancements of Gene Editing Technology for Safe and Effective Gene Therapy Products 27Dec December 27, 2023 Quality Assurance and Compliance 26Sep September 26, 2023 Navigating Drug Manufacturing Inspections 18Sep September 18, 2023 How does EMA use Artificial Intelligence and Large Language Models in Medicine Regulation? 31May May 31, 2023 Understanding the FDA’s Abbreviated New Animal Drug Application Pathway 08Dec December 8, 2022 Convergence of regulatory frameworks surrounding cell, tissue, and gene therapy products 16Jun June 16, 2022 Technological transformation in Pharmacovigilance 18May May 18, 2022 Nanobodies vs antibodies in the fight against Covid 05May May 5, 2022 Enhancing drug discovery processes through artificial intelligence 19Apr April 19, 2022 The impact of the Russia-Ukraine war on clinical trials 13Apr April 13, 2022 The First WHO Global Centre For Traditional Medicine in Gujurat, India 06Apr April 6, 2022 DDReg’s RegTech space: your regulatory solution for achieving rapid market access 25Feb February 25, 2022 Biologics development & regulatory approval – EMA perspective 11Feb February 11, 2022 Biosimilarity and Interchangeability in the MENA region 23Jan January 23, 2022 Biosimilars in the Emerging World 01Dec December 1, 2021 All About African Medicines Agency 16Nov November 16, 2021 What is Role of Integrative Medicine in Healthcare? 21Oct October 21, 2021 Knowledge Management in Regulatory Affairs (KMRA) 16Sep September 16, 2021 Telehealth – Regulatory Perspective 27Aug August 27, 2021 Expanded use of RWE (Real World Evidence) 13Aug August 13, 2021 Artificial Intelligence – Impact on The Global Pharma Industry 03Aug August 3, 2021 Identification of Medicinal Products (IDMP) – The Perspective of US FDA & EMA 26Mar March 26, 2021 Controlled Correspondence with FDA – An Update 28Oct October 28, 2020 Generic Drug User Fee Amendments 28Oct October 28, 2020 Impact of Brexit on the Pharmaceutical Industry 28Oct October 28, 2020 Nitrosamine Impurities: A Regulatory Perspective
